NASDAQ:AKAO - Achaogen Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00
+0.30 (1.20%)
Get New Achaogen Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AKAO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AKAO

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
This price target is based on 0 analysts offering 12 month price targets for Achaogen in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.
N/A
The current consensus among 0 contributing investment analysts is to n/a stock in Achaogen. This rating has held steady since March 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 8 hold ratings
  • 0 sell ratings
9/8/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
12/7/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/6/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/4/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/2/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/1/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/30/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/1/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/29/2019Needham & Company LLCReiterated RatingHoldLow
i
2/21/2019HC WainwrightReiterated RatingHold$2.00High
i
Rating by E. Arce at HC Wainwright
2/15/2019MizuhoReiterated RatingHold$3.00High
i
11/13/2018SunTrust BanksReiterated RatingBuy ➝ Hold$10.00 ➝ $3.00Medium
i
11/12/2018HC WainwrightReiterated RatingBuy ➝ Neutral$19.00 ➝ $3.00High
i
Rating by E. Arce at HC Wainwright
11/12/2018WedbushDowngradeOutperform ➝ Neutral$17.00 ➝ $3.00High
i
Rating by R. Driscoll at Wedbush
11/9/2018GabelliDowngradeBuy ➝ HoldHigh
i
Rating by Kevin Kedra at Gabelli
11/9/2018Stifel NicolausDowngradeBuy ➝ HoldHigh
i
11/9/2018CowenDowngradeOutperform ➝ Market PerformHigh
i
11/9/2018MizuhoDowngradeBuy ➝ NeutralHigh
i
11/6/2018MizuhoReiterated RatingBuy ➝ Neutral$8.00 ➝ $8.00Low
i
8/20/2018SunTrust BanksLower Price TargetBuy$16.00 ➝ $10.00Low
i
8/7/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$14.00 ➝ $22.00Medium
i
8/7/2018Needham & Company LLCDowngradeBuy ➝ HoldMedium
i
7/27/2018CowenReiterated RatingBuyLow
i
6/27/2018WedbushLower Price TargetOutperform ➝ Outperform$21.00 ➝ $20.00High
i
Rating by R. Driscoll at Wedbush
5/7/2018GuggenheimDowngradeBuy ➝ Neutral$17.00High
i
5/4/2018SunTrust BanksLower Price TargetBuy$16.00High
i
5/3/2018MizuhoReiterated RatingBuyHigh
i
4/30/2018Needham & Company LLCReiterated RatingBuy$20.00High
i
4/30/2018HC WainwrightReiterated RatingBuy$19.00 ➝ $29.00High
i
3/4/2018SVB LeerinkReiterated RatingOutperformLow
i
Rating by A. Fadia at SVB Leerink LLC
3/1/2018HC WainwrightLower Price TargetBuy ➝ Buy$31.00 ➝ $29.00High
i
2/28/2018William BlairReiterated RatingOutperformHigh
i
Rating by Y. Xu at William Blair
2/28/2018Stifel NicolausLower Price TargetBuy ➝ Buy$27.00 ➝ $23.00Medium
i
2/28/2018Needham & Company LLCReiterated RatingBuy ➝ Buy$29.00 ➝ $20.00Medium
i
2/14/2018WedbushReiterated RatingPositive ➝ Outperform$28.00 ➝ $22.00High
i
Rating by Robert Driscoll at Wedbush
2/7/2018HC WainwrightBoost Price TargetBuy ➝ Buy$25.00 ➝ $31.00Medium
i
1/10/2018GuggenheimReiterated RatingBuy$14.00High
i
1/3/2018MizuhoReiterated RatingBuy$28.00High
i
1/3/2018SunTrust BanksLower Price TargetBuy$27.00High
i
11/30/2017MizuhoReiterated RatingBuy$28.00High
i
11/9/2017Stifel NicolausLower Price TargetBuy ➝ Buy$30.00 ➝ $27.00N/A
i
11/9/2017HC WainwrightReiterated RatingPositive ➝ Buy$25.00N/A
i
Rating by E. Arce at HC Wainwright
11/9/2017MizuhoReiterated RatingBuy$28.00N/A
i
10/30/2017MizuhoReiterated RatingBuy$28.00N/A
i
10/24/2017GuggenheimInitiated CoverageBuy$17.00N/A
i
10/9/2017SVB LeerinkReiterated RatingOutperform ➝ Outperform$28.00 ➝ $22.00N/A
i
9/28/2017MizuhoReiterated RatingBuy$28.00Medium
i
9/6/2017MizuhoInitiated CoverageBuy$28.00High
i
8/4/2017Stifel NicolausReiterated RatingBuy$30.00High
i
6/15/2017HC WainwrightInitiated CoverageBuy ➝ Buy$29.00Medium
i
Rating by E. Arce at HC Wainwright
5/15/2017CowenReiterated RatingOutperformN/A
i
Rating by Ritu Baral at Cowen Inc
5/9/2017Stifel NicolausReiterated RatingBuy ➝ Buy$28.00 ➝ $31.00Low
i
5/5/2017CowenReiterated RatingOutperformLow
i
Rating by Ritu Baral at Cowen Inc
4/24/2017WedbushReiterated RatingOutperform$28.00High
i
Rating by R. Driscoll at Wedbush
3/30/2017AegisDowngradeBuy ➝ Hold$29.00Low
i
3/15/2017WedbushReiterated RatingOutperform$28.00Medium
i
Rating by R. Driscoll at Wedbush
3/15/2017Needham & Company LLCReiterated RatingBuy$29.00Medium
i
3/15/2017AegisReiterated RatingBuy$39.00High
i
3/15/2017Stifel NicolausBoost Price TargetBuy ➝ Buy$27.00 ➝ $28.00High
i
3/6/2017WedbushBoost Price TargetOutperform$23.00 ➝ $28.00N/A
i
Rating by R. Driscoll at Wedbush
3/2/2017WedbushReiterated RatingOutperform ➝ Outperform$23.00 ➝ $28.00N/A
i
Rating by R. Driscoll at Wedbush
3/2/2017Needham & Company LLCBoost Price TargetBuy ➝ Buy$19.00 ➝ $29.00N/A
i
2/23/2017AegisBoost Price TargetBuy$20.00 ➝ $29.00N/A
i
2/7/2017Stifel NicolausInitiated CoverageBuy$27.00N/A
i
1/31/2017WedbushInitiated CoverageOutperform$19.00 ➝ $23.00N/A
i
Rating by Heather Behanna at Wedbush
1/24/2017GuggenheimReiterated RatingBuy$30.00N/A
i
1/23/2017GuggenheimInitiated CoverageBuy ➝ PositiveN/A
i
1/4/2017SVB LeerinkInitiated CoverageOutperform$21.00N/A
i
Rating by P. Matteis at SVB Leerink LLC
12/15/2016WedbushReiterated RatingOutperform$10.00 ➝ $19.00N/A
i
12/13/2016CowenReiterated RatingBuyN/A
i
Rating by Ritu Baral at Cowen Inc
12/12/2016Needham & Company LLCUpgradeHold ➝ Buy$19.00N/A
i
11/28/2016CowenUpgradeMarket Perform ➝ OutperformN/A
i
11/22/2016WedbushReiterated RatingOutperform$10.00N/A
i
11/8/2016CowenReiterated RatingHoldN/A
i
11/8/2016WedbushReiterated RatingOutperform$10.00N/A
i
11/2/2016AegisInitiated CoverageBuy$10.00N/A
i
9/27/2016WedbushReiterated RatingOutperform$10.00N/A
i
9/26/2016SunTrust BanksReiterated RatingBuy$10.00N/A
i
8/9/2016Needham & Company LLCReiterated RatingHoldN/A
i
Rating by Alan Carr at Needham & Company LLC
6/14/2016WedbushUpgradeNeutral ➝ Outperform$7.00 ➝ $10.00N/A
i
Rating by H. Behanna at Wedbush
5/9/2016Needham & Company LLCReiterated RatingHoldN/A
i
Rating by Alan Carr at Needham & Company LLC
5/6/2016WedbushReiterated RatingNeutral$7.00N/A
i
3/31/2016CowenDowngradeOutperform ➝ Market PerformN/A
i
3/16/2016Needham & Company LLCDowngradeBuy ➝ HoldN/A
i
3/15/2016WedbushReiterated RatingNeutral$10.00 ➝ $7.00N/A
i
(Data available from 3/1/2016 forward)
Achaogen logo
Achaogen, Inc., a late-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae. It is also involved in the development of antibacterial candidate C-Scape, an orally-administered combination of clavulanate and ceftibuten, which targets serious bacterial infections due to expanded spectrum beta-lactamases producing enterobacteriaceae; and therapeutic antibody discovery program. The company has license and collaboration agreements with Thermo Fisher Scientific, Inc. to develop and commercialize an assay to support plazomicin; Crystal Biosciences, Inc. to discover monoclonal antibodies against multiple targets; Ionis Pharmaceuticals, Inc. for certain patents relating to aminoglycoside antibacterial compounds and related know-how to develop and commercialize certain novel aminoglycoside antibacterial compounds; and Hovione Limited to manufacture the active pharmaceutical ingredient for plazomicin. The company was incorporated in 2002 and is based in South San Francisco, California.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $0.11
$0.11
$0.11

52 Week Range

Now: N/A

Volume

N/A

Average Volume

3,341,029 shs

Market Capitalization

$7.03 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.78

Frequently Asked Questions

What sell-side analysts currently cover shares of Achaogen?

The following sell-side analysts have issued reports on Achaogen in the last year:
View the latest analyst ratings for AKAO.

What is the current price target for Achaogen?

0 Wall Street analysts have set twelve-month price targets for Achaogen in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Achaogen in the next year.
View the latest price targets for AKAO.

What is the current consensus analyst rating for Achaogen?

Achaogen currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for AKAO.

What other companies compete with Achaogen?

How do I contact Achaogen's investor relations team?

Achaogen's physical mailing address is 1 TOWER PLACE SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company's listed phone number is 650-800-3636 and its investor relations email address is [email protected] The official website for Achaogen is www.achaogen.com.